Variation in adjuvant and early salvage radiotherapy after robot-assisted radical prostatectomy for prostate cancer: a population-based cohort study

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Belgian Cancer Registry. Cancer fact sheet prostate cancer Belgium 2016. Available from: https://kankerregister.org/Cancer_Fact_Sheets
   Google Scholar
• Hager B, Kraywinkel K, Keck B, et al. Increasing use of radical prostatectomy for locally advanced prostate cancer in the USA and Germany: a comparative population-based study. Prostate Cancer Prostatic Dis. 2017;20(1):61–66.
   PubMed Web of Science ®Google Scholar
• Albisinni S, Joniau S, Quackels T, et al. Current trends in patient enrollment for robotic-assisted laparoscopic prostatectomy in Belgium. Cancer. 2017;123(21):4139–4146.
   PubMed Web of Science ®Google Scholar
• Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;28(3):555–565.
   PubMed Web of Science ®Google Scholar
• Spahn M, Weiss C, Bader P, et al. Long-term outcome of patients with high-risk prostate cancer following radical prostatectomy and stage-dependent adjuvant androgen deprivation. Urol Int. 2010;84(2):164–173.
   PubMed Web of Science ®Google Scholar
• Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380(9858):2018–2027.
   PubMed Web of Science ®Google Scholar
• Wiegel T, Bartkowiak D, Bottke D, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96–02/AUO AP 09/95. Trial Eur Urol. 2014;66(2):243–250.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181(3):956–962.
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–629.
   PubMed Web of Science ®Google Scholar
• Pisansky TM, Thompson IM, Valicenti RK, et al. Adjuvant and salvage radiotherapy after prostatectomy: ASTRO/AUA Guideline Amendment 2018–2019. J Urol. 2019;202(3):533–538.
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. JCO. 2007;25(15):2035–2041.
   PubMed Web of Science ®Google Scholar
• Wiegel T, Lohm G, Bottke D, et al. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome—results of a retrospective study. Int J Radiat Oncol. 2009;73(4):1009–1016.
   PubMed Web of Science ®Google Scholar
• Ost P, De Troyer B, Fonteyne V, et al. A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol. 2011;80(5):1316–1322.
   PubMed Web of Science ®Google Scholar
• Parker C, Clarke N, Logue J, et al. RADICALS (radiotherapy and androgen deprivation in combination after local surgery). Clin Oncol. 2007;19(3):167–171.
   PubMed Web of Science ®Google Scholar
• Richaud P, Sargos P, Henriques de Figueiredo B, et al. GETUG AFU 17. Radiothérapie postopératoire des cancers de la prostate. Cancer/Radiothérapie. 2010;14(6–7):500–503.
   Google Scholar
• Pearse M, Fraser-Browne C, Davis ID, et al. A phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the radiotherapy – adjuvant versus early salvage (RAVES) trial. BJU Int. 2014;113(Suppl 2):7–12.
   PubMed Web of Science ®Google Scholar
• Vale CL, Brihoum M, Chabaud S, et al. Adjuvant or salvage radiotherapy for the treatment of localised prostate cancer? A prospectively planned aggregate data meta-analysis. Ann Oncol. 2019;30:883.
   Web of Science ®Google Scholar
• Sheets NC, Hendrix LH, Allen IM, et al. Trends in the use of postprostatectomy therapies for patients with prostate cancer: a surveillance, epidemiology, and end results medicare analysis. Cancer. 2013;119(18):3295–3301.
   PubMed Web of Science ®Google Scholar
• Sineshaw HM, Gray PJ, Efstathiou JA, et al. Declining use of radiotherapy for adverse features after radical prostatectomy: results from the national cancer database. Eur Urol. 2015;68(5):768–774.
   PubMed Web of Science ®Google Scholar
• Epstein JI, Allsbrook WC, Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29(9):1228–1242.
   PubMed Web of Science ®Google Scholar
• Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2015;40(2):1–52.
   Web of Science ®Google Scholar
• Björnberg A, Phang AY. Euro Health Consumer Index Report 2018. Avaiable from: https://healthpowerhouse.com/publications/
   Google Scholar
• Grau C, Defourny N, Malicki J, et al. Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol. 2014;112(2):155–164.
   PubMed Web of Science ®Google Scholar
• Fowler FJ, Jr, Collins MM, Albertsen PC, et al. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA. 2000;283(24):3217–3222.
   PubMed Web of Science ®Google Scholar
• Lievens Y, De Schutter H, Stellamans K, et al. Radiotherapy access in Belgium: how far are we from evidence-based utilisation.? Eur J Cancer. 2017;84:102–113.
   PubMed Web of Science ®Google Scholar
• Jin CJ, Hanna TP, Cook EF, et al. Variation in radiotherapy referral and treatment for high-risk pathological features after radical prostatectomy: results from a population-based study. Clin Oncol. 2018;30(1):47–56.
   Web of Science ®Google Scholar
• Hawken SR, Spratt DE, Qi J, et al. Utilization of salvage radiation therapy for biochemical recurrence after radical prostatectomy. Int J Radiat Oncol. 2019; 104(5):1030–1034.
   PubMed Web of Science ®Google Scholar